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Abstract 
We previously reported transplantation of brain microvascular endothelial cells (MVECs) into 
cerebral white matter infarction model improved the animal’s behavioral outcome by increasing the 
number of oligodendrocyte precursor cells (OPCs). We also revealed extracellular vesicles (EVs) 
derived from MVECs promoted survival and proliferation of OPCs in vitro. In this study, we 
investigated the mechanism how EVs derived from MVECs contribute to OPC survival and 
proliferation. Protein mass spectrometry and enzyme-linked immunosorbent assay revealed 
fibronectin was abundant on the surface of EVs from MVECs. As fibronectin has been reported to 
promote OPC survival and proliferation via integrin signaling pathway, we blocked the binding 
between fibronectin and integrins using RGD sequence mimics. Blocking the binding, however, did 
not attenuate the survival and proliferation promoting effect of EVs on OPCs. Flow cytometric and 
imaging analyses revealed fibronectin on EVs mediates their internalization into OPCs by its binding 
to heparan sulfate proteoglycan on OPCs. OPC survival and proliferation promoted by EVs were 
attenuated by blocking the internalization of EVs into OPCs. These lines of evidence suggest that 
fibronectin on EVs mediates their internalization into OPCs, and the cargo of EVs promotes survival 
and proliferation of OPCs, independent of integrin signaling pathway. 
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1. Introduction 
Demyelination induced by subcortical ischemia contributes to motor and cognitive deficit [1,2]. 
There is no established treatment against white matter demyelination. We previously reported 
transplantation of brain microvascular endothelial cells (MVECs) into the white matter infarction 
reduced infarction area and improved motor deficit [3]. We also reported transplanted MVECs 
promoted survival of oligodendrocyte precursor cells (OPCs) [4]. Our in vitro analysis revealed 
extracellular vesicles (EVs) derived from MVECs promoted OPC survival and proliferation [5]. 
EVs are small vesicles containing proteins, lipids and nucleic acids, and are involved in intercellular 
communication [6]. We suppose some of these molecules contribute to promotion of OPC survival 
and proliferation and elucidation of the mechanism may lead to establishment of the novel 
therapeutics against white matter infarction. 
In this study, we analyzed the molecular mechanism how EVs derived from MVECs 
(MVEC-EVs) affect OPC behavior, focusing on proteins. Protein mass spectrometry and 
enzyme-linked immunosorbent assay (ELISA) revealed fibronectin is abundant on the surface of 
MVEC-EVs. Although fibronectin is reported to promote survival and proliferation of OPCs via 
integrin signaling pathway [7], we couldn’t attenuate the effects of EVs on OPCs by blocking the 
binding between fibronectin and integrins. Recently, heparan sulfate proteoglycan (HSPG) is 
reported to be the endocytosis receptor for EVs [8,9]. We found EV uptake was decreased by 
interfering the interaction between fibronectin on EVs and HSPG on OPCs. The decrease in the EV 
uptake attenuated their survival/proliferation promoting effect on OPCs. These results indicate 
fibronectin on the surface of EVs contributes to their internalization into OPCs and thereby promotes 
OPC survival and proliferation.  
 
2. Materials and methods 
2.1. Ethics statement 
All experiments were performed in accordance with the guidelines for Animal Experimentation 
at Gunma University Graduate School of Medicine and were approved by Gunma University Ethics 
Committee (Permit Number:16-009).  
 2.2. Animals 
We used Sprague-Dawley rats (SLC, Japan) in this study (postnatal day 2 pups for OPC culture, 
and eight-week-old male rats for MVEC culture). Rats were sacrificed by decapitation under deep 
anesthesia to obtain the brains. 
 
2.3. Cell culture  
OPCs were prepared from postnatal day 2 rat brain cortices by immunopanning as previously 
described [5,10]. OPCs were plated into poly-D-lysine (PDL, Sigma)-coated dish, supplemented with 
forskolin (Sigma), ciliary neurotrophic factor, neurotrophin-3 and platelet-derived growth factor-AA 
(all obtained from PeproTech). After 3 days, OPCs were plated on PDL-coated 8-well slide glasses 
for survival and proliferation assays or on PDL-coated 35 mm culture dishes for flow cytometry. 
MVECs were prepared from adult rat cerebra as previously described [5]. We used MVECs to 
collect EVs when the cells reached >95% confluent. The contaminating cells were below 10%.  
Rat fibroblast-like cell line (Rat-1) was cultured in DMEM (Wako) containing 5% fetal bovine 
serum (FBS). 
 
2.4. Isolation of EVs from culture media 
For EV isolation, cells were cultured in medium containing exosome-depleted FBS (System 
Biosciences) (MVECs: EGM-2 containing 2% exosome-depleted FBS, Rat-1: DMEM containing 5% 
exosome-depleted FBS) for 72 h. To isolate EVs, except for mass spectrometry, we used the 
exosome precipitation solution, ExoQuick-TC (System Biosciences), according to the manufacture’s 
protocol. EV pellet was suspended in serum-free medium or phosphate buffered saline (PBS). EV 
isolation for mass spectrometry was performed using MagCapture Exosome Isolation Kit PS (Wako) 
according to the manufacture’s protocol. Protein concentration was measured using Protein 
Quantification Assay Kit (Takara Bio) according to the manufacturer’s protocol.  
 
2.5. Protein mass spectrometry 
The surface protein peptide library of isolated MVEC-EVs was prepared using XPEP Exosome 
Mass Spec Kit (System Biosciences) according to the manufacture’s protocol. Mass spectrometry 
was performed with Eksgent Ekspert NanoLC 425 (AB Sciex) coupled to TripleTOF 6600 mass 
spectrometer (AB Sciex). Peptide mixture was separated by ODS column 
(Eksigent ChromXP-C18-CL, 3 µm, 120Å, 0.075 mm I.D. ×150 mm L, AB Sciex) with 2-30% 
acetonitrile gradient containing 0.1% formic acid for 60 min. Proteins were identified using Mascot 
sequence matching software (Matrix Science) [11] with SwissProt database. 
 
2.6. ELISA 
MVEC-EVs were treated with 5 mIU/ml heparitinase (heparin lyase III, HL) (Sigma) for 3 h at 
37°C or 0.25% trypsin (TR) (Sigma) for 10 min at 37°C. Treated EVs were suspended in PBS, and 
pelleted using ExoQuick-TC. The pellets were resuspended in PBS. Quantification of fibronectin on 
the surface of EVs was performed using rat fibronectin ELISA kit (abcam) according to the 
manufacturer’s protocol. Samples (50 µl/well) containing 6 µg of EV proteins were added to each 
well. 
 
2.7. Analysis using integrin function inhibitory peptides 
To assess the interaction between fibronectin on EVs and integrins on OPCs, we used peptide 
mimics (RGD peptides) of fibronectin binding: an antagonist peptide (Gly-Arg-Gly-Asp-Ser 
[GRGDS]) of integrin function, an inhibitory peptide (Gly-Arg-Gly-Asp-Thr-Pro [GRGDTP]) of 
fibronection, type-1 collagen and vitronectin, and a negative control peptide 
(Gly-Arg-Ala-Asp-Ser-Pro-Lys [GRADSPK]) that does not block integrin binding (all obtained from 
Sigma). OPCs cultured on 8-well slide glass were washed with PBS, and incubate with serum-free 
medium containing 300 µg/ml peptides for 30 min. After incubation, MVEC-EVs were added to 
OPC culture at 50 µg/ml of EV proteins. After 1 day’s culture, OPC survival and proliferation were 
assayed. 
 
2.8. Cell survival assay 
Cell death with the typical morphological features of apoptosis including pyknotic nuclei was 
assessed by staining cell nuclei with Hoechst 33342 (Sigma, 2.5 μ M) for 40 min in 5% CO2 at 37°C. 
Samples were observed using a fluorescent microscope (Axioplan2, Zeiss) with cooled CCD camera 
(DP73, Olympus), and the number of pyknotic cells was counted.  
 
2.9. BrdU incorporation assay 
To assess cell proliferation, bromodeoxyuridine (BrdU; 10 μ M) (Roche Diagnostics) was 
added to the cultures for the last 4 h of culture, followed by fixation and staining with rat monoclonal 
BrdU antibody (abcam; 1:1000). Propidium iodide (PI, Sigma, 2 μg/ml) was used for nuclear 
staining. Samples were observed using a fluorescent microscope with cooled CCD camera, and the 
number of BrdU-positive cells in each sample was counted. 
 
2.10. Treatments of the surface of EVs and OPCs 
To investigate the involvement of fibronectin and glycosaminoglycans (heparan sulfate and 
heparin) in the uptake of EVs by OPCs, EVs and OPCs were treated with heparitinase, heparin, 
fibronectin, or RGD peptides (All obtained from Sigma) as follows; 
Treatment 1) To remove heparan sulfate on EVs, EVs were treated with 5 mIU/ml 
heparitinase at 37°C for 3 h, and suspended in PBS. 
Treatment 2) To remove heparan sulfate on the surface of OPCs, OPCs were treated with 0.5 
mIU/ml heparitinase at 37°C for 3 h prior to addition of EVs. 
Treatment 3) To block heparin-binding domain of fibronectin on EVs, EVs were incubated 
with 50 µg/ml heparin for 30 min. The heparin-bound EVs were collected using ExoQuick-TC. 
Treatment 4) To block fibronectin-binding sites on OPCs, the cells were preincubated with 
200 µg/ml human plasma fibronectin (Sigma) for 1 h prior to addition of EVs. 
Treatment 5) To block the interaction between fibronectin on EVs and integrins on OPCs, 
OPCs were preincubated with 100 µg/ml antagonist peptide (GRGDS) for 1 h prior to addition of 
EVs. 
 
2.11. Flow cytometry and image analysis 
In these analyses, we used fluorescent dye PKH67-labeled EVs prepared according to the 
manufacturer’s protocol (Sigma). All experiments were performed at 200 µg/ml of EV proteins. 
PKH67-labeled EVs treated with heparitinase (Treatment 1) or heparin (Treatment 3) were added to 
untreated OPCs. OPCs treated with hepatitinase (Treatment 2) or fibronectin (Treatment 4) or an 
antagonist peptide (Treatment 5) were cultured in serum-free medium containing untreated 
PKH67-labeled EVs. Untreated OPCs cultured with untreated PKH67-labeled EVs were also 
prepared. In any treatment, after 3 h in culture, OPCs were harvested, suspended in PBS containing 
0.2% BSA, and loaded on Attune® Acoustic Focusing Cytometer (Thermo Fisher) for measurement 
of fluorescent intensity of individual cells. As control, untreated OPCs were measured. Data were 
analyzed by FlowJo software (ver. 7.6.5. TOMY Digital Biology). Cells were observed using a 
fluorescent microscope with cooled CCD camera. Fluorescent intensity of individual cells was 
analyzed by ImageJ software (ver. 1.513, NIH). 
 
2.12. Analysis of the involvement of glycosaminoglycans in EV-OPC interactions 
To assess the involvement of glysosaminoglycans present on the surface of EVs or OPCs, in 
OPC survival and proliferation, we treated EVs or OPCs with heparitinase or heparin (Treatments 
1-3 as mentioned above). Untreated or heparitinase-treated (Treatment 2) OPCs were cultured in the 
serum-free medium with or without 50 µg/ml untreated EVs. Untreated OPCs were cultured in the 
serum-free medium containing 50 µg/ml EVs treated with heparitinase (Treatment 1) or heparin 
(Treatment 3). In any treatment, after 1 day in culture, cell survival and proliferation were assayed.  
 
2.13. Statistical analysis 
Statistical analysis was performed using EZR software (ver. 1.32) [12]. Differences between 
groups were assessed with one-way analyses of variance followed by the post hoc Tukey–Kramer 
test. The error bars represent the standard errors. 
 
3. Results  
3.1. Fibronectin is abundant on the surface of the MVEC-EVs 
 First, in order to investigate what proteins exist on the surface of EVs, we performed protein 
mass spectrometric analysis of the surface proteins of the MVEC-EVs. Fibronectin was found 
present on the surface of EVs (Fig. 1A). To quantify the amount of fibronectin on EV surface, we 
performed ELISA and found fibronectin on the surface of the MVEC-EVs was much more abundant 
as compared with that on Rat-1-EV surface (Fig. 1). We previously reported Rat-1-EVs also promote 
OPC survival but much less effectively compared to MVEC-EVs [5]. The difference in the amount 
of fibronectin between MVEC-EVs and Rat-1-EVs may cause the survival promoting difference. 
 
3.2. Fibronectin on the surface of EVs does not contribute to their survival and proliferation 
promoting effect on OPCs via binding to integrins on OPCs 
 Fibronectin binds to integrins [13], and the integrin signaling promotes OPC survival and 
proliferation [7, 14–17]. Fibronectin on EVs are also reported to activate the integrin pathway and 
cause biological responses [18, 19]. So, we examined if fibronectin on EVs promotes OPC survival 
and proliferation by binding to integrins. 
 Fibronectin binds to integrins by RGD (Arginine - Glycine - Aspartic acid) domain [20]. To 
assess the involvement of fibronectin-integrin binding in the effects of EVs on OPCs, we blocked the 
interaction between fibronectin on EVs and integrins on OPCs by using RGD sequence mimics. 
 As shown in Fig. 2, MVEC-EVs reduced pyknotic OPC deaths and increased proportion of 
BrdU-positive OPCs compared to control, in accordance with our previous report [5]. Pretreatment 
of OPCs with RGD sequence mimics, thereby blocking the binding of fibronectin to integrins on 
OPCs, did not attenuate the effects of EVs on OPCs. These results suggest the survival/proliferation 
effect of EVs on OPCs is not mediated by integrin signaling. 
 
3.3. Fibronectin on EVs mediates their internalization into OPCs 
 From the results above, we concluded that EVs did not promote OPC survival or proliferation 
via stimulation of integrins by fibronectin, but their cargo affected OPCs. So, we examined the role 
for fibronectin in internalization of EVs into OPCs. 
 Although the exact mechanism of internalization of EVs into target cells is controversial [8, 9, 
21–26], HSPG on the target cell membrane was reported to be the receptor for EV uptake [8, 9]. It is 
also reported that HSPG exists on EVs [8, 9] and these vesicles capture fibronectin by their HSPG 
and captured fibronectin, in turn, binds to the HSPG on the target cells. This interaction between 
fibronectin on EVs and HSPG on target cells may trigger the internalization [9]. To quantify the 
internalization, we labeled EVs with PKH67, a fluorescent dye, and administered them to OPCs 
under various conditions described below and performed flow cytometric and imaging analyses.  
1) Untreated EVs were administered to OPCs that had been treated with heparitinase (Fig. 3A).  
2) EVs treated with heparitinase were administered to untreated OPCs (Fig. 3B).  
3) EVs preincubated with heparin were administered to untreated OPCs. (Fig. 3C) 
4) Untreated EVs were administered to OPCs preincubated with fibronectin (Fig. 3D). 
5) Untreated EVs were administered to OPC preincubated with GRGDS, an RGD sequence mimic 
(Fig. 3E).  
As shown in Fig. 3A and Supplementary Fig. 1A and B, EV uptake into OPCs was decreased by 
treating OPCs with heparitinase, suggesting HSPG on OPCs is the receptor for EVs endocytosis. EV 
uptake was also decreased by treating EVs with heparitinase (Fig. 3B, Supplementary Fig. 1A and B). 
ELISA revealed the amount of fibronectin was decreased by the same enzymatic treatment (Fig. 1B), 
indicating a part of fibronectin adheres to HSPG on EVs. Preincubation of OPCs with fibronectin 
attenuated uptake of EVs by them (Fig. 3D, Supplementary Fig.1A and B), suggesting fibronectin on 
EVs is a ligand for internalization. Heparin, a mimic of HSPG, also attenuated EV uptake by OPCs 
(Fig. 3C, Supplementary Fig.1A and B). In contrast, preincubation of OPCs with GRGDS peptide 
did not interfere with EV uptake by them (Fig. 3E). Taken together, these results suggest a part of 
fibronectin is tethered to HSPG on EVs and the EV uptake by OPCs is mediated by the binding of 
fibronectin to HSPG on OPCs (Supplementary Fig. 2).  
 
3.4. Decrease in EV uptake by OPCs attenuates their survival/proliferation promoting effect on 
OPCs 
 We next investigated whether decrease in EV uptake by OPCs results in attenuation of OPC 
survival/proliferation promoting effect. As shown in Fig. 4, any intervention which attenuated uptake 
of EVs by OPCs reduced their survival and proliferation promoting effect on OPCs. These findings 
suggest that EVs affect OPCs after their internalization into these cells. 
 
4. Discussion 
 We revealed fibronectin is abundant on the surface of MVEC-EVs. A part of fibronectin is 
tethered to HSPG on EVs, and this fibronectin contributes to EV internalization into OPCs by 
binding to HSPG on these cells. Importantly, decrease in EV uptake attenuated their 
survival/proliferation promoting effect on OPCs. 
 We also revealed that treating OPCs with heparitinase greatly reduced incorporation of EVs 
into these cells. We interpret this result as HSPG on OPCs acts as the receptor for fibronectin on EVs. 
There is, however, a possibility that HSPG on OPCs plays a role for internalization of EVs, 
independent of fibronectin. HSPG is reported to be the endocytosis receptor [27], and there is a 
report that EV internalization occurs through endocytosis [21-26]. Although the exact mechanism 
how HSPG is involved in endocytosis is unknown [28], small GTPases are presumed to play a role 
for this process. Syndecan-4, a HSPG, activates RhoG [29, 30], which, in turn, induces α5β1 integrin 
endocytosis in a dynamin- and caveolin-dependent manner [30]. Syndecan-4 also activates Arf6 [31], 
which is involved in the clathrin-dependent endocytosis of angiotensin II type 1 receptor [32]. 
HSPG-mediated clathrin- and cavaeolin-independent endocytosis is also reported [33]. Further study 
is needed to elucidate the exact mechanism of HSPG-mediated internalization of EVs. 
 Although integrin signaling has been reported to promote survival and proliferation of OPCs [7, 
13–17], we found the effect of EVs on OPCs was not attenuated by blocking the binding between 
fibronectin and integrins. One possible reason for this difference may be that the amount of 
fibronectin on EVs was not enough to directly activate integrins on OPCs. We did not try higher 
amounts of EVs in this study, but there is a possibility that fibronectin on EVs directly activates 
integrins on OPCs, if higher amounts of EVs are administered to the cells. 
 The exact mechanism how MVEC-EVs promote OPC survival and proliferation is still 
unknown. EVs contain many kinds of miRNA which regulate gene expression [34]. We presume 
miRNAs are candidates for promoting OPC survival and proliferation. For example, miR-17-92 
cluster promotes OPC proliferation by influencing Akt pathway [35]. This miRNA cluster also 
targets phosphatase and tensin homolog deleted on chromosome 10 (PTEN), which is known to be a 
negative regulator of neural stem cell proliferation and survival [36]. MicroRNA-146a decreased 
OPC apoptosis by attenuating IRAK1 [37]. We are now trying to identify the molecules in 
MVEC-derived EVs that promote OPC survival and proliferation. 
 Recently, EVs are attracting attention as possible tools for treatment of central nervous system 
diseases [38]. The exact mechanism of EV uptake by neural cells in central nervous system, however, 
still remains unknown. This is the first report on the uptake pathway of EVs into OPCs. Further 
study is needed to elucidate the detailed mechanism of EV uptake by neural cells to develop a novel 
therapeutic strategy using EVs. 
 
Conflicts of interest 
 The authors declare no conflict of interests.  
 
Acknowledgements 
 We thank Dr. Touko Hirano (Laboratory for Analytical Instruments, Education and Research 
Support Center, Gunma University Graduate School of Medicine) and Ms. Kao Abe (Department of 
Molecular and Cellular Neurobiology, Gunma University Graduate School of Medicine) for 
excellent technical assistance. We also thank Bioresource Center at Gunma University Graduate 
School of Medicine. This work was supported by Grants-in-Aid for Scientific Research from the 
Japan Society for the Promotion of Science to M. Kurachi (grant numbers 15K15448, 17K10291) 
and Y. Ishizaki (grant number 16K10710). This work was also supported by Grants-in-Aid from the 
Ministry of Education, Culture, Sports, Science and Technology of Japan for programs for Leading 
Graduate Schools, Cultivating Global Leaders in Heavy Ion Therapeutics and Engineering. 
 
References 
 
[1] M. Samuelsson, B. Söderfeldt, G.B. Olsson, Functional outcome in patients with lacunar 
infarction., Stroke. 27 (1996) 842–846. 
[2] T. Yan, J.-R. Yu, Y.-P. Zhang, T. Li, Analysis on correlation of white matter lesion and lacunar 
infarction with vascular cognitive impairment., Int. J. Clin. Exp. Med. 8 (2015) 14119–14122.  
[3] S. Puentes, M. Kurachi, K. Shibasaki, et al., Brain microvascular endothelial cell 
transplantation ameliorates ischemic white matter damage., Brain Res. 1469 (2012) 43–53.  
[4] K. Iijima, M. Kurachi, K. Shibasaki, et al., Transplanted microvascular endothelial cells 
promote oligodendrocyte precursor cell survival in ischemic demyelinating lesions., J. 
Neurochem. 135 (2015) 539–550.  
[5] M. Kurachi, M. Mikuni, Y. Ishizaki, Extracellular vesicles from vascular endothelial cells 
promote survival, proliferation and motility of oligodendrocyte precursor cells., PLoS One. 11 
(2016) e0159158. 
[6] Z.G. Zhang, M. Chopp, Exosomes in stroke pathogenesis and therapy., J. Clin. Invest. 126 
(2016) 1190–1197.  
[7] J. Hu, L. Deng, X. Wang, X.-M. Xu, Effects of extracellular matrix molecules on the growth 
properties of oligodendrocyte progenitor cells in vitro., J. Neurosci. Res. 87 (2009) 2854–2862.  
[8] H.C. Christianson, K.J. Svensson, T.H. van Kuppevelt, et al., Cancer cell exosomes depend on 
cell-surface heparan sulfate proteoglycans for their internalization and functional activity., Proc. 
Natl. Acad. Sci. U. S. A. 110 (2013) 17380–17385.  
[9] A. Purushothaman, S.K. Bandari, J. Liu, et al., Fibronectin on the surface of myeloma 
cell-derived exosomes mediates exosome-cell interactions., J. Biol. Chem. 291 (2016) 1652–
1663.  
[10] J.R. Chan, T.A. Watkins, J.M. Cosgaya, et al., NGF controls axonal receptivity to myelination 
by Schwann cells or oligodendrocytes., Neuron. 43 (2004) 183–191.  
[11]  D.N. Perkins, D.J. Pappin, D.M. Creasy, J.S. Cottrell, Probability-based protein identification 
by searching sequence databases using mass spectrometry data., Electrophoresis, 20 
(1999) 3551-3567. 
[12] Y. Kanda, Investigation of the freely available easy-to-use software “EZR” for medical 
statistics., Bone Marrow Transplant. 48 (2013) 452–458.  
[13] R.W.O. Meara, J. Michalski, R. Kothary, et al., Integrin signaling in oligodendrocytes and its 
importance in CNS myelination, J. Signal Transduct. 2011 (2011) 1–11.  
[14] K.L. Blaschuk, E.E. Frost, C. Ffrench-Constant, The regulation of proliferation and 
differentiation in oligodendrocyte progenitor cells by alphaV integrins., Development. 127 
(2000) 1961–1969.  
[15] K.K. Lee, Y. de Repentigny, R. Saulnier, et al., Dominant-negative beta1 integrin mice have 
region-specific myelin defects accompanied by alterations in MAPK activity., Glia. 53 (2006) 
836–844.  
[16] E.E. Frost, P.C. Buttery, R. Milner, C. ffrench-Constant, Integrins mediate a neuronal survival 
signal for oligodendrocytes., Curr. Biol. 9 (1999) 1251–1254.  
[17] H. Colognato, W. Baron, V. Avellana-Adalid, et al., CNS integrins switch growth factor 
signalling to promote target-dependent survival., Nat. Cell Biol. 4 (2002) 833–841.  
[18] S. Atay, C. Gercel-Taylor, D.D. Taylor, Human trophoblast-derived exosomal fibronectin 
induces pro-inflammatory IL-1β production by macrophages., Am. J. Reprod. Immunol. 66 
(2011) 259–269. 
[19] S. Atay, C.D. Roberson, C. Gercel-taylor, D.D. Taylor, Ovarian cancer-derived exosomal 
fibronectin induces pro-inflammatory IL-1β, Exosomes and Microvesicles. 1 (2013) 1–10.  
[20] E. Ruoslahti, RGD and other recognition sequences for integrins., Annu. Rev. Cell Dev. Biol. 
12 (1996) 697–715.  
[21] T. Tian, Y.-L. Zhu, Y.-Y. Zhou, et al., Exosome uptake through clathrin-mediated endocytosis 
and macropinocytosis and mediating miR-21 delivery., J. Biol. Chem. 289 (2014) 22258–
22267.  
[22] T. Tian, Y. Wang, H. Wang, et al., Visualizing of the cellular uptake and intracellular trafficking 
of exosomes by live-cell microscopy., J. Cell. Biochem. 111 (2010) 488–496.  
[23] L.A. Mulcahy, R.C. Pink, D.R.F. Carter, Routes and mechanisms of extracellular vesicle 
uptake., J. Extracell. Vesicles. 3 (2014) 1–14.  
[24] I. Nakase, N.B. Kobayashi, T. Takatani-Nakase, T. Yoshida, Active macropinocytosis 
induction by stimulation of epidermal growth factor receptor and oncogenic Ras expression 
potentiates cellular uptake efficacy of exosomes., Sci. Rep. 5 (2015) 10300.  
[25] C. Escrevente, S. Keller, P. Altevogt, J. Costa, Interaction and uptake of exosomes by ovarian 
cancer cells., BMC Cancer. 11 (2011) 108.  
[26] D. Feng, W.L. Zhao, Y.Y. Ye, et al., Cellular internalization of exosomes occurs through 
phagocytosis, Traffic. 11 (2010) 675–687.  
[27] H.C. Christianson, M. Belting, Heparan sulfate proteoglycan as a cell-surface endocytosis 
receptor., Matrix Biol. 35 (2014) 51–55.  
[28] S. Sarrazin, W.C. Lamanna, J.D. Esko, Heparan sulfate proteoglycans., Cold Spring Harb. 
Perspect. Biol. 3 (2011) 1–33.  
[29] A. Elfenbein, J.M. Rhodes, J. Meller, et al., Suppression of RhoG activity is mediated by a 
syndecan 4-synectin-RhoGDI1 complex and is reversed by PKCalpha in a Rac1 activation 
pathway., J. Cell Biol. 186 (2009) 75–83.  
[30] M.D. Bass, R.C. Williamson, R.D. Nunan, et al., A syndecan-4 hair trigger initiates wound 
healing through caveolin- and RhoG-regulated integrin endocytosis., Dev. Cell. 21 (2011) 681–
693.  
[31] R. Brooks, R. Williamson, M. Bass, Syndecan-4 independently regulates multiple small 
GTPases to promote fibroblast migration during wound healing., Small GTPases. 3 (2012) 73–
79.  
[32] M.-E. Poupart, D. Fessart, M. Cotton, et al., ARF6 regulates angiotensin II type 1 receptor 
endocytosis by controlling the recruitment of AP-2 and clathrin., Cell. Signal. 19 (2007) 2370–
2378.  
[33] C.K. Payne, S.A. Jones, C. Chen, X. Zhuang, Internalization and trafficking of cell surface 
proteoglycans and proteoglycan-binding ligands., Traffic. 8 (2007) 389–401.  
[34] B.W.M. van Balkom, A.S. Eisele, D.M. Pegtel, et al., Quantitative and qualitative analysis of 
small RNAs in human endothelial cells and exosomes provides insights into localized RNA 
processing, degradation and sorting., J. Extracell. Vesicles. 4 (2015) 26760.  
[35] H. Budde, S. Schmitt, D. Fitzner, et al., Control of oligodendroglial cell number by the 
miR-17-92 cluster., Development. 137 (2010) 2127–2132.  
[36] Z.G. Zhang, M. Chopp, Promoting brain remodeling to aid in stroke recovery., Trends Mol. 
Med. 21 (2015) 543–548.  
[37] X.S. Liu, M. Chopp, W.L. Pan, et al., MicroRNA-146a promotes oligodendrogenesis in stroke., 
Mol. Neurobiol. 54 (2017) 227–237.  
[38] L. Braccioli, C. van Velthoven, C.J. Heijnen, Exosomes: a new weapon to treat the central 
nervous system., Mol. Neurobiol. 49 (2014) 113–119.   
  
Fig. 1. Fibronectin is abundant on the surface of the MVEC-EVs. 
(A) Protein mass spectrometry indicated fibronectin (FINC) was present on the surface of 
MVEC-EVs. (B) The amount of fibronectin in MVEC-EVs or Rat-1 cells, with or without enzymatic 
treatments (Tx, hepatitinase; HL, trypsin; TR), was quantified by ELISA. Results are shown as mean 
± SE (N = 4 in each condition). *p < 0.05 compared with MVEC-EVs. #p < 0.05 compared with 
MVEC-EVs treated with HL. 
 
 
 
 
 
 
 
 
  
Fig. 2. MVEC-EVs promote OPC survival and proliferation but these effects are not blocked 
by RGD sequence mimics. 
OPCs were preincubated with or without an integrin antagonist peptide (GRGDS), an inhibitory 
peptide of fibronection, type 1 collagen or vitronectin (GRGDTP), or a negative control peptide 
(GRADSPK) for 30 min. MVEC-EVs were added to OPC cultures and maintained for 1 day. Results 
are shown as mean ± SE (N = 8 in each condition). *p < 0.05 compared with control (EVs(-)/peptide 
mimic(-)). #p < 0.05 compared with EVs(-)/peptide mimic(+) sample. These experiments were 
repeated three times, and similar results were obtained each time. Typical experiments are shown 
here. 
 
 
  
Fig. 3. The internalization of EVs into OPCs is attenuated by blocking the interaction between 
fibronectin and HSPG.  
Flow cytometric analysis revealed EVs uptake into OPCs were attenuated by interfering the 
interaction between fibronectin and HSPG. (A) OPCs were treated with 0.5 mIU/ml heparitinase 
(HL) at 37°C for 3 h. (B) EVs were treated with 5 mIU/ml HL at 37°C for 3 h. (C) EVs were 
preincubated with 50 µg/ml heparin (HP) for 30 min. (D) OPCs were preincubated with 200 µg/ml 
plasma fibronectin (FN) for 1 h. (E) OPCs were preincubated with 100 µg/ml GRGDS. These 
experiments were repeated three times, and similar results were obtained each time. Typical 
experiments are shown here. 
 
 
 Fig. 4.  The promoting effect of EVs on OPC survival and proliferation is diminished by 
blocking the interaction between fibronectin and HSPG. 
(A, D) OPCs were treated (Tx) with or without 0.5 mIU/ml heparitinase (HL) at 37°C for 3 h. EVs 
were added after the enzymatic treatment. *p < 0.05 compared to control (EVs(-)/OPC-Tx(-)). #p < 
0.05 compared to EVs(+)/OPC-Tx(-). $p < 0.05 compared to EVs(+)/OPC-Tx(HL). (B, E) EVs were 
treated with or without 5 mIU/ml HL at 37°C for 3 h. *p < 0.05 compared to control (EVs(-)). #p < 
0.05 compared to EVs treated with HL (EV-Tx(HL)). (C, F) EVs were preincubated with or without 
50 µg/ml heparin (HP) for 30 min. *p < 0.05 compared to control (EVs(-)). #p < 0.05 compared to 
EVs conjugated with HP (EV-Tx(HP)). These experiments were repeated three times, and similar 
results were obtained each time. Typical experiments are shown here. Results are shown as mean ± 
SE (N = 8 in each condition). 
 
